David Spellman
Plus aucun poste en cours
Fortune : 817 064 $ au 31/03/2024
Profil
David A.
Spellman formerly worked at Vertex Pharmaceuticals, Inc., as VP-Commercial & International Finance, Mersana Therapeutics, Inc., as Chief Financial Officer from 2018 to 2019, Intarcia Therapeutics, Inc., as Chief Financial & Business Officer from 2019 to 2020, and Akebia Therapeutics, Inc., as Treasurer, Chief Financial & Accounting Officer from 2022 to 2023.
Mr. Spellman received his undergraduate degree from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/05/2023 | 446 483 ( 0,21% ) | 817 064 $ | 31/03/2024 |
Anciens postes connus de David Spellman
| Sociétés | Poste | Fin |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Director of Finance/CFO | 23/06/2023 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Director of Finance/CFO | 29/06/2020 |
| MERSANA THERAPEUTICS, INC. | Director of Finance/CFO | 30/06/2019 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Formation de David Spellman
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
